Dabrafenib in 2D vs 3D melanoma models
2024
University of Malta, Msida, Malta
Melanoma, the most lethal form of skin cancer, remains a major clinical challenge due to the lack of effective early treatment models. This study investigated the impact of the BRAF inhibitor dabrafenib on melanoma by applying a high-throughput workflow for drug screening to both 2D and 3D cell culture models. Metastatic melanoma cells with the BRAF V600E mutation and normal melanocytes were cultured in 2D monolayers and 3D spheroids, and treated with varying concentrations of dabrafenib. A series of in vitro assays was conducted to assess the effects on cell viability, aggregation, migration, cell cycle progression, and apoptosis. Dabrafenib was shown to reduce cell viability, inhibit cellular adhesion and aggregation, impede migration, induce G1 cell cycle arrest, and promote apoptosis, particularly in the melanoma cell line. These results confirm the therapeutic potential of dabrafenib in treating melanoma with the BRAF V600E mutation, and demonstrate that 3D models are validated systems for studying new molecules for therapeutic purposes.
Comparative analysis of the effect of the BRAF inhibitor dabrafenib in 2D and 3D cell culture models of human metastatic melanoma cells
Marion Zammit-Mangion, David Tovar-Parra
Added on: 08-05-2024
[1] https://iv.iiarjournals.org/content/38/4/1579
